Status:

COMPLETED

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Lead Sponsor:

AstraZeneca

Conditions:

Perennial Allergic Rhinitis

Allergic Rhinitis

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergi...

Eligibility Criteria

Inclusion

  • Main
  • General good health, other than perennial allergic rhinitis
  • History and diagnosis of perennial allergic rhinitis by skin prick test
  • Main

Exclusion

  • Participation in any investigational drug trial within the 30 days preceding the Screening Visit
  • A known hypersensitivity to any corticosteroid or any of the excipients in the formulation
  • Use of any prohibited concomitant medications as defined by the study protocol

Key Trial Info

Start Date :

December 1 2003

Trial Type :

INTERVENTIONAL

End Date :

April 1 2005

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT00163501

Start Date

December 1 2003

End Date

April 1 2005

Last Update

November 30 2016

Active Locations (41)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (41 locations)

1

Altana Pharma/Nycomed

Encinitas, California, United States, 92024

2

Altana Pharma/Nycomed

Huntington Beach, California, United States, 92647

3

Altana Pharma/Nycomed

Long Beach, California, United States, 90806

4

Altana Pharma/Nycomed

Los Angeles, California, United States, 90025